| Schlenk, Richard F |
| Completed | 2 | 43 | Europe | Palbociclib, Ibrance | University Hospital Heidelberg | Chordoma | 12/22 | 12/22 | | |
| Recruiting | 2 | 28 | Europe | Pembrolizumab, PEM, Keytruda®, Azacitidine, AZA, Vidaza® | Technische Universität Dresden, Merck Sharp & Dohme LLC | Acute Myeloid Leukemia | 12/25 | 12/26 | | |
| Completed | 2 | 102 | Europe | Olaparib, Physician's choice, Trabectedin | National Center for Tumor Diseases, Heidelberg, AstraZeneca, PharmaMar, German Cancer Research Center | Cancers With DNA Repair-Deficiency | 12/23 | 12/23 | | |
| Active, not recruiting | 2 | 21 | Europe, US, RoW | GB2064 | Galecto Biotech AB, OPIS s.r.l | Myelofibrosis | 12/23 | 06/26 | | |
NCT04410653: Afatinib in Advanced NRG1-Rearranged Malignancies |
|
|
| Completed | 2 | 3 | Europe | Afatinib 40 MG | German Cancer Research Center, German Consortium for Translational Cancer Research | Metastatic and Locally Advanced NRG1-rearranged Malignancies | 10/23 | 10/23 | | |
PAMSARC, NCT06456359: Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor |
|
|
| Recruiting | 2 | 28 | Europe | Signifor, ATC-Code: H01CB05 | University Hospital Heidelberg | Desmoplastic Small Round Cell Tumor, Synovial Sarcoma | 10/27 | 10/28 | | |
| Recruiting | 2 | 1000 | Europe | Atezolizumab, Futibatinib, TAS-120, Amivantamab, JNJ-372 | Vall d'Hebron Institute of Oncology, Roche Pharma AG, Iqvia Pty Ltd, Taisho Pharmaceutical Co., Ltd., Janssen, LP | Advanced Solid Tumor | 05/25 | 11/26 | | |
| Completed | 2 | 72 | Europe | Vemurafenib, Cobimetinib, Atezolizumab, Trastuzumab, Pertuzumab, Alectinib, Ipatasertib, Inavolisib | German Cancer Research Center, German Cancer Research Center, Roche Pharma AG | Metastatic or Locally Advanced Malignancies | 12/24 | 12/24 | | |
| Recruiting | 1/2 | 214 | Europe | MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO, Rydapt, Mylotarg, MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO, MAGNOLIA-trial: conventional chemotherapy (AraC+DNR)+GO, MAGMA-trial:GO associated with conventional chemotherapy (AraC+DNR)+Midostaurin, MAGMA-trial: conventional chemotherapy (AraC+DNR)+Midostaurin | Technische Universität Dresden, Novartis Pharmaceuticals, Pfizer | Acute Myeloid Leukemia | 04/27 | 04/28 | | |
| Recruiting | 1 | 86 | Europe | CC-1, PSMAxCD3 | University Hospital Tuebingen, German Cancer Research Center | Castration-Resistant Prostatic Cancer | 12/25 | 12/25 | | |
NCT02192619: National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup |
|
|
| Recruiting | N/A | 500 | Europe | observational | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | Newly-diagnosed APL (de Novo or Therapy-related), Relapsed APL | 12/24 | 12/24 | | |
| Recruiting | N/A | 1000 | Europe | Sublingual in vivo microscopy with the Glycocheck microscope | Prof. Dr. Thomas Luft | Hematological Neoplasm, Endothelial Dysfunction | 06/27 | 06/32 | | |
| Recruiting | N/A | 3000 | Europe | | Prof. Dr. Richard F Schlenk | Sarcoma, Malignant Mesenchymoma, Sarcoma of Bone and Connective Tissue | 07/30 | 12/32 | | |
| Recruiting | N/A | 1000 | Europe | | University Hospital Heidelberg | Myeloid Neoplasm | 07/30 | 12/32 | | |
| Döhner, Hartmut |
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics |
|
|
| Recruiting | 3 | 882 | Europe | Cytarabine, Daunorubicin, CPX-351 | University of Ulm, Jazz Pharmaceuticals | Acute Myeloid Leukemia | 06/27 | 06/27 | | |
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy |
|
|
| Active, not recruiting | 3 | 777 | Europe, RoW | Gilteritinib, ASP2215, Midostaurin, Rydapt | Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc. | Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 | 10/25 | 06/33 | | |
NCT04628026: Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 |
|
|
| Recruiting | 3 | 650 | Europe | Venetoclax, Placebo, Standard chemotherapy, Autologous stem cell transplantation, Allogeneic stem cell transplantation | University of Ulm, Stichting Hemato-Oncologie voor Volwassenen Nederland | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 02/25 | 02/31 | | |
NCT06652438: Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML |
|
|
| Not yet recruiting | 3 | 415 | Europe | Revumenib, Placebo | Stichting Hemato-Oncologie voor Volwassenen Nederland, German-Austrian Acute Myeloid Leukemia Study Group, United Kingdom AML Research Network | Acute Myeloid Leukemia, Adult | 05/28 | 05/31 | | |
AMLSG BiO, NCT01252485: Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - the Biology and Outcome (BiO)-Project |
|
|
| Recruiting | N/A | 50000 | Europe | | University of Ulm | Acute Myeloid Leukemia (AML), MDS/AML | 12/44 | 12/44 | | |
| Doehner, Hartmut |
NCT02013648: Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) |
|
|
| Completed | 3 | 204 | Europe | Dasatinib, Sprycel, Cytarabine, ARA-cell, Daunorubicin, Daunoblastin, Idarubicin | University of Ulm | Acute Myeloid Leukemia (AML) | 02/24 | 02/24 | | |
NCT04628026: Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 |
|
|
| Recruiting | 3 | 650 | Europe | Venetoclax, Placebo, Standard chemotherapy, Autologous stem cell transplantation, Allogeneic stem cell transplantation | University of Ulm, Stichting Hemato-Oncologie voor Volwassenen Nederland | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 02/25 | 02/31 | | |
| Recruiting | 1/2 | 413 | Europe, Canada, US, RoW | revumenib, SNDX-5613, cobicistat | Syndax Pharmaceuticals, Syndax Pharmaceuticals, Inc | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage | 12/27 | 12/27 | | |
|
|
|
|
|
|
|
|
|
| Ettrich, Thomas J |
| Completed | 3 | 430 | Europe | Ramucirumab, TAS 102 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Eli Lilly and Company, Trium Analysis Online GmbH | Colorectal Cancer | 07/24 | 07/24 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
| Active, not recruiting | 3 | 450 | Europe, Japan, US, RoW | Regorafenib, Stivarga, Nivolumab, Opdivo, Docetaxel, Taxotere, Paclitaxel, Abraxane, Irinotecan, Camptosar, Trifluridine/Tipracil, Lonsurf | Australasian Gastro-Intestinal Trials Group, Bayer, Bristol-Myers Squibb, University of Sydney, Academic and Community Cancer Research United, Taiwanese Cooperative Oncology Group, Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, National Cancer Center Hospital East, Syneos Health | Gastro-Oesophageal Cancer | 06/25 | 06/26 | | |
NCT05008809: Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418) |
|
|
| Recruiting | 3 | 507 | Europe | mFOLFOX6, Folinic acid, Oxaliplatin, 5-fluorouracil (FU), mFOLFOXIRI, Folinic acid, Oxaliplatin, 5-FU, Irinotecan, FOLFIRI, Folinic acid, 5-FU, CAPOX, Capecitaine, Oxaliplatin | Dominik Paul Modest, German Research Foundation, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Colorectal Cancer | 11/27 | 11/30 | | |
RAMIRIS, NCT03081143 / 2015-005171-24: Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients with Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy |
|
|
| Active, not recruiting | 2/3 | 429 | Europe | FOLFIRI, Ramucirumab, Paclitaxel | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Advanced Gastric or EGJ Cancer | 12/25 | 12/25 | | |
| Active, not recruiting | 2 | 93 | Europe | Arm NaI-IRI + 5-FU + Leucovorin (Arm A), Arm Cisplatin + Gemcitabine (Arm B) | AIO-Studien-gGmbH, Servier, Institut für Klinisch-Onkologische Forschung der Krankenhaus Nordwest GmbH | Adenocarcinoma Metastatic, Biliary Tract Cancer, Adenocarcinoma of the Biliary Tract, Adenocarinoma Locally Advanced, Non-Resectable Hepatocellular Carcinoma, Intrahepatic Bile Duct Carcinoma, Extrahepatic Bile Duct Carcinoma | 01/22 | 01/25 | | |
| Recruiting | 2 | 35 | Europe | FOLFIRI Protocol, SCO-101 | Scandion Oncology A/S, TFS Trial Form Support | Metastatic Colorectal Cancer | 06/22 | 06/22 | | |
FUTURE, NCT06722183: Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities |
|
|
| Not yet recruiting | 2 | 33 | Europe | Futibatinib orally administered, Tislelizumab (i.v. 200mg) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Universitätsmedizin Mainz, I. Medizinische Klinik, Forschungslabor Prof. Möhler | Colorectal Cancer | 06/27 | 06/27 | | |
NCT04511455: Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment |
|
|
| Completed | 2 | 22 | Europe | Cabozantinib | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Ipsen | Hepatocellular Carcinoma Non-resectable, Metastatic Hepatocellular Carcinoma | 12/24 | 12/24 | | |
PANTAX-Ib, NCT04652206: Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients. |
|
|
| Recruiting | 1/2 | 18 | Europe | SCO-101, Gemcitabine, Nab paclitaxel | Scandion Oncology A/S, Alcedis GmbH | Metastatic Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Inoperable Disease, Localized Pancreatic Adenocarcinoma | 03/22 | 05/22 | | |
| Schönland, Stefan |
AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy |
|
|
| Recruiting | 3 | 482 | Europe | Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD), daratumumab/bortezomib/dexamethasone (DVD), daratumumab/lenalidomide/dexamethasone (DRD), ixazomib/lenalidomide/dexamethasone (IRD), pomalidomide/bortezomib/dexamethasone (PVD), carfilzomib/daratumumab/dexamethasone (KDD), Autologous Stem Cells, daratumumab/pomalidomide/dexamethasone (DPD), isatuximab/carfilzomib/dexamethasone (Isa-KD), selinexor/bortezomib/dexamethasone (SVD) | Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH | Multiple Myeloma | 03/28 | 03/33 | | |
| Active, not recruiting | 2 | 35 | Europe | Belantamab mafodotin | Stichting European Myeloma Network, GlaxoSmithKline | AL Amyloidosis | 07/25 | 07/25 | | |
EUREKA, NCT06205953: A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis |
|
|
| Recruiting | N/A | 400 | Europe, RoW | | Fondazione IRCCS Policlinico San Matteo di Pavia | AL Amyloidosis | 06/26 | 06/26 | | |
| Paschka, Peter |
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics |
|
|
| Recruiting | 3 | 882 | Europe | Cytarabine, Daunorubicin, CPX-351 | University of Ulm, Jazz Pharmaceuticals | Acute Myeloid Leukemia | 06/27 | 06/27 | | |
| Greiner, Jochen |
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics |
|
|
| Recruiting | 3 | 882 | Europe | Cytarabine, Daunorubicin, CPX-351 | University of Ulm, Jazz Pharmaceuticals | Acute Myeloid Leukemia | 06/27 | 06/27 | | |
COVIC-19, NCT05271929: Early High-Titre Convalescent Plasma in Clinically Vulnerable Individuals With Mild COVID-19 |
|
|
| Terminated | 3 | 120 | Europe | Current standard of care and COVID-19 convalescent and vaccinated plasma, Current standard of care | Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen, NHS Blood and Transplant, Erasmus Medical Center | COVID-19 | 01/24 | 06/24 | | |
NCT04628026: Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 |
|
|
| Recruiting | 3 | 650 | Europe | Venetoclax, Placebo, Standard chemotherapy, Autologous stem cell transplantation, Allogeneic stem cell transplantation | University of Ulm, Stichting Hemato-Oncologie voor Volwassenen Nederland | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 02/25 | 02/31 | | |
AMLSG BiO, NCT01252485: Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - the Biology and Outcome (BiO)-Project |
|
|
| Recruiting | N/A | 50000 | Europe | | University of Ulm | Acute Myeloid Leukemia (AML), MDS/AML | 12/44 | 12/44 | | |
NCT03125707: German MPN-Registry for BCR-ABL 1-Negative Myeloid Neoplasms (Study Group Ulm) |
|
|
| Recruiting | N/A | 2172 | Europe | Registry study | University of Ulm | BCR-ABL1-Negative Myeloid Neoplasms | 09/45 | 09/45 | | |
| Fink, Angelina |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
CA209-9MJ, NCT03543189: Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy |
|
|
| Active, not recruiting | 1/2 | 44 | US | Nivolumab, Opdivo®, Brachytherapy, HDR Brachytherapy, External Beam Radiation Therapy, Radiotherapy, EBRT, Androgen Deprivation Therapy, ADT | H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb | Prostate Cancer, Prostate Disease | 12/25 | 12/26 | | |
HiPPo, NCT06627348: Hilotherapy for Prevention of Chemotherapy-induced Peripheral Polyneuropathy |
|
|
| Recruiting | N/A | 150 | Europe | Hilotherm ChemoCare | University of Ulm, Hilotherm | Equipment and Supplies | 03/27 | 03/27 | | |
| Sala, Elisa |
AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy |
|
|
| Recruiting | 3 | 482 | Europe | Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD), daratumumab/bortezomib/dexamethasone (DVD), daratumumab/lenalidomide/dexamethasone (DRD), ixazomib/lenalidomide/dexamethasone (IRD), pomalidomide/bortezomib/dexamethasone (PVD), carfilzomib/daratumumab/dexamethasone (KDD), Autologous Stem Cells, daratumumab/pomalidomide/dexamethasone (DPD), isatuximab/carfilzomib/dexamethasone (Isa-KD), selinexor/bortezomib/dexamethasone (SVD) | Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH | Multiple Myeloma | 03/28 | 03/33 | | |
PHOEBUS, NCT05762211: Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications ( Trial) |
|
|
| Recruiting | 2 | 387 | Europe | Pooled allogeneic fecal microbiotherapy, MaaT033, Placebo | MaaT Pharma | Transplant Complication | 10/26 | 02/27 | | |
RESOLVE AML001, NCT06281847: An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia |
|
|
| Not yet recruiting | 1/2 | 143 | Europe | CCTx-001 | Advesya SAS | Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | 07/25 | 08/41 | | |
NCT04230265: Dose-escalating Trial With UniCAR02-T Cells and CD123 Target Module (TM123) in Patients With Hematologic and Lymphatic Malignancies |
|
|
| Recruiting | 1 | 90 | Europe | Cyclophosphamide (Non-IMP), Fludarabine (Non-IMP), TM123 (IMP), UniCAR02-T (IMP) | AvenCell Europe GmbH, PHARMALOG Institut für klinische Forschung GmbH | Acute Myeloid Leukemia (AML) | 05/25 | 09/25 | | |
NCT05949125: Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123 |
|
|
| Recruiting | 1 | 37 | Europe | Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), R-TM123, R-TM123 is one component of the Allo-RevCAR01-T-CD123 treatment, Allo-RevCAR01-T, Allo-RevCAR01-T is one component of the Allo-RevCAR01-T-CD123 treatment | AvenCell Europe GmbH, Allucent (NL) BV | Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | 12/25 | 06/26 | | |
TAP-NSCLC, NCT06050278: Prospective Evaluation of Single Cell Mutations in a Panel of Known Oncogenes in NSCLC Surgical Specimens |
|
|
| Recruiting | N/A | 10 | Europe | Tapestry technology | University of Milano Bicocca | NSCLC | 08/24 | 04/26 | | |
| Recruiting | N/A | 150 | Europe, RoW | No Intervention | Takeda | Cytomegalovirus (CMV) | 04/25 | 04/25 | | |
| Kapp-Schwoerer, Silke |
IMGN632-0802, NCT04086264: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia |
|
|
| Active, not recruiting | 1/2 | 218 | Europe, US | Azacitidine, Vidaza, Decitabine, IMGN632, CD123-targeted ADC, Venetoclax, Venclexta, Venclyxto | AbbVie, Jazz Pharmaceuticals | Acute Myeloid Leukemia | 04/26 | 04/26 | | |
| Rueker, Frank |
IMGN632-0802, NCT04086264: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia |
|
|
| Active, not recruiting | 1/2 | 218 | Europe, US | Azacitidine, Vidaza, Decitabine, IMGN632, CD123-targeted ADC, Venetoclax, Venclexta, Venclyxto | AbbVie, Jazz Pharmaceuticals | Acute Myeloid Leukemia | 04/26 | 04/26 | | |
| Sagir, Ayten |
IMGN632-0802, NCT04086264: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia |
|
|
| Active, not recruiting | 1/2 | 218 | Europe, US | Azacitidine, Vidaza, Decitabine, IMGN632, CD123-targeted ADC, Venetoclax, Venclexta, Venclyxto | AbbVie, Jazz Pharmaceuticals | Acute Myeloid Leukemia | 04/26 | 04/26 | | |
NCT02576496: Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies |
|
|
| Completed | 1 | 106 | Europe, US | Tinostamustine, EDO-S101 | Mundipharma Research Limited | Hematological Malignancies, Multiple Myeloma, Hodgkin's Lymphoma, Cutaneous T Cell Lymphoma | 05/23 | 11/23 | | |
| Knull, Miriam |
AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy |
|
|
| Recruiting | 3 | 482 | Europe | Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD), daratumumab/bortezomib/dexamethasone (DVD), daratumumab/lenalidomide/dexamethasone (DRD), ixazomib/lenalidomide/dexamethasone (IRD), pomalidomide/bortezomib/dexamethasone (PVD), carfilzomib/daratumumab/dexamethasone (KDD), Autologous Stem Cells, daratumumab/pomalidomide/dexamethasone (DPD), isatuximab/carfilzomib/dexamethasone (Isa-KD), selinexor/bortezomib/dexamethasone (SVD) | Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH | Multiple Myeloma | 03/28 | 03/33 | | |
